Article
Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals malignancy.
Nature communications - 20 Sept 2021
Takamatsu Kimiharu, Tanaka Nobuyuki, Hakozaki Kyohei, Takahashi Ryohei, Teranishi Yu, Murakami Tetsushi, Kufukihara Ryohei, Niwa Naoya, Mikami Shuji, Shinojima Toshiaki, Sasaki Takashi, Sato Yusuke, Kume Haruki, Ogawa Seishi, Kakimi Kazuhiro, Kamatani Takashi, Miya Fuyuki, Tsunoda Tatsuhiko, Aimono Eriko, Nishihara Hiroshi, Sawada Kazuaki, Imamura Takeshi, Mizuno Ryuichi, Oya Mototsugu
Abstract excerpt
A cutting edge therapy for future immuno-oncology is targeting a new series of inhibitory receptors (IRs): LAG-3, TIM-3, and TIGIT. Both immunogenomic analyses and diagnostic platforms to distinguish candidates and predict good responders to these IR-related agents are vital in clinical pathology. By applying an automated single-cell count for immunolabelled LAG-3, TIM-3, and TIGIT, we reveal that individual IR...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
